Drug Profile

Lead 212 NG 001

Alternative Names: ²¹²Pb NG001; AB-001-ARTBIO; Lead-212 NG001

Latest Information Update: 06 Nov 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator ARTBIO
Class Antineoplastics; Imaging agents; Lead radioisotopes; Peptide diagnostics; Peptide drug conjugates; Radiopharmaceutical diagnostics; Radiopharmaceuticals
Mechanism of Action Emission-computed tomography enhancers; Ionising radiation emitters; Single-photon emission-computed tomography enhancers

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

27 Oct 2025 Phase-I clinical trials in Prostate cancer (Metastatic disease, Late-stage disease, Hormone refractory, Second-line therapy or greater) in USA (Injection) (NCT07214961)
09 Sep 2025 US FDA approves IND application for Lead 212 NG 001 (AB001) in Prostate cancer
09 Sep 2025 ARTBIO plans a phase I trial for Prostate cancer in USA

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com